Attached files

file filename
10-K - FORM 10-K - BIODELIVERY SCIENCES INTERNATIONAL INCd298257d10k.htm
EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - BIODELIVERY SCIENCES INTERNATIONAL INCd298257dex322.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - BIODELIVERY SCIENCES INTERNATIONAL INCd298257dex312.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - BIODELIVERY SCIENCES INTERNATIONAL INCd298257dex311.htm
EX-23.1 - CONSENT OF CHERRY BEKAERT LLP - BIODELIVERY SCIENCES INTERNATIONAL INCd298257dex231.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - BIODELIVERY SCIENCES INTERNATIONAL INCd298257dex211.htm
EX-10.36 - TERMINATION AGREEMENT - BIODELIVERY SCIENCES INTERNATIONAL INCd298257dex1036.htm
EX-10.35 - AMENDED AND RESTATED CLINICAL DEVELOPMENT AND LICENSE AGREEMENT - BIODELIVERY SCIENCES INTERNATIONAL INCd298257dex1035.htm

Exhibit 32.1

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(18 U.S.C. 1350)

Pursuant to Section 906 of the Sarbanes-Oxley Act of (18 U.S.C. 1350), the undersigned officer of BioDelivery Sciences International, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of such officer’s knowledge and belief, that:

(1) The Annual Report on Form 10-K for the year ended December 31, 2016 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Form 10-K fairly presents, in all materials respects, the financial condition and results of operations of the Company.

 

Date: March 16, 2017    

/s/ Mark A. Sirgo

    Mark A. Sirgo, President, Chief Executive Officer and Vice Chairman

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Securities Exchange Act.